Did you know that the U.S. NASH Action Plan is the first and only national action plan created to address the growing epidemic of NASH? In 2021, GLI NASH Council partners...
As the world continues to gain a better understanding of COVID-19 and ever present and new variants, Global Liver Institute wants to ensure that we are here to continue to guide, educate, and...
(Washington, D.C., May 3, 2022) – Global Liver Institute (GLI), a premier patient-led liver health nonprofit operating globally, is deeply concerned by the draft opinion published...
(Washington, D.C., April 29, 2022) – As leaders in the liver cancer community, Global Liver Institute and their Liver Cancers team expresses our gratitude and recognizes Dr. Ned Sharpless and...
Welcome to the very first edition of Pediatric & Rare Liver Diseases News! As we expand our offerings for and about this community, Global Liver Institute is also committed to keeping...
Today, April 6, the members of the Liver Action Network (LAN) pledge our collective support for Living Donor Day to honor the donors, recipients, families and caregivers, and clinical teams that...
Transforming Global Consciousness of Liver Health through Education and Advocacy (Washington, D.C., March 30, 2022) – Global Liver Institute (GLI), a patient-led liver health nonprofit...
New Season, New Format: Striving to meet the needs of the expanding liver health- interested community for timely information on must-know events and news specific to our Council communities...
Interested in learning more? Check out what GLI’s President and CEO Donna Cryer, JD has to say on Season 3, Episode 12 of Surfing the NASH Tsunami here. Nonalcoholic steatohepatitis (NASH) has a...
Global Liver Institute Launches Final Nonalcoholic Steatohepatitis (NASH) Externally-Led Patient-Focused Drug Development Meeting Outcome Report (Washington, DC, Wednesday, March 9,...
Recent News
Global Liver Institute Statement on the Passing of Dr. Stephen HarrisonThe entire field of liver health has experienced an incredible loss. It is with great sadness that Global Liver Institute, our Liver Action Network members and the patient community express our...
Addressing Disparities in Organ Transplantation: A Call for Equitable Healthcare Introduction Organ transplantation has revolutionized modern medicine, offering a beacon of hope for individuals battling end-stage organ failure. At the same time, it is intricately...
Congress begins Fiscal Year 2025 appropriations process and the Administration approves new treatments improving the lives of liver disease patients. Join Global Liver Institute to Push Congress to Advance Priority Bills and Support Agency Efforts.Congress finalizes...
New App Helps Predict Pediatric Transplant Need Celebrating the repurposed use of Livmarli for pediatric rare liver disease patients Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s...
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S. This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development. The hope...
